BRIEF

on VALNEVA (EPA:VLA)

Valneva Publishes Findings on Chikungunya Impact in British Medical Journal

Stock price chart of VALNEVA (EPA:VLA) showing fluctuations.

Valneva SE announced the publication of a study in The British Medical Journal analyzing the global health and economic impact of chikungunya from 2011 to 2020. The study highlights a broader disease burden and significant costs associated with chikungunya, which could strain health systems due to its unpredictable nature.

The analysis revealed 18.7 million reported cases in 110 countries, leading to 1.95 million disability-adjusted life years lost. The financial impact reached $2.8 billion in direct costs and $47.1 billion in indirect expenses, with the majority of cases in Latin America and the Caribbean.

Climate change is contributing to year-round mosquito-borne disease threats, potentially increasing chikungunya outbreaks. WHO has marked chikungunya as a major public health concern. Valneva underscores the necessity for these insights to guide prevention and response strategies worldwide.

R. P.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all VALNEVA news